The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 7 rounds in the feed, most often in Biotech.
Venture capital4biocapital.comRounds from 2022-01-04 to 2026-11-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Oyster Therapeutics A pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven diseases like Alzheimer’s | Series A Verified against 4 of 21 sources | $60M | 2026-11-10 | [ LEAD ] |
Undecimal Bio A spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics | Seed |
| $18M |
| 2026-10-12 |
| [ LEAD ] |
Aptadir Therapeutics A preclinical biotech company developing a new class of RNA therapeutics | Seed Verified against 1 of 40 sources | $44.7M | 2026-09-29 | [ LEAD ] |
Ray Therapeutics Optogenetic therapies designed to restore functional vision for people with degenerative retinal diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-04-21 | [ PART ] |
Estuary Biotherapeutics A biotechnology company developing genetic medicines for patients with serious kidney diseases | Series A Verified against 1 of 14 sources | $93M | ~ 2025-05-30 | [ PART ] |
Ray Therapeutics Optogenetic therapies designed to restore functional vision for people with degenerative retinal diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2023-05-16 | [ PART ] |
Ray Therapeutics Optogenetic therapies designed to restore functional vision for people with degenerative retinal diseases. | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $6M | 2022-01-04 | [ LEAD ] |